Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00883168 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
A Phase 3 study, sponsored by Meda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,791
- Enrollment target
NCT00883168 is a Phase 3 study that has completed, run by Meda Pharmaceuticals. The registered enrollment target is 1,791 participants.
The verdict
NCT00883168, a Phase 3 study, has completed, sponsored by Meda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,791 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the combination of two allergy medications (formulated azelastine/fluticasone product)is more effective than placebo or either component medication alone (azelastine or fluticasone).
Interventions
- DRUG Placebo
- DRUG fluticasone propionate
- DRUG azelastineHcl
- DRUG azelastine Hcl/fluticasone propionate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,791 participants |
| Start Date | 2009-04 |
| Est. Completion | 2009-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00883168
The ClinicalTrials.gov registry entry for NCT00883168 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,791 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Meda Pharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00883168 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00883168 about?
NCT00883168 is a clinical study titled "A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies". The purpose of this study is to determine if the combination of two allergy medications (formulated azelastine/fluticasone product)is more effective than placebo or either component medication alone (azelastine or fluticasone).
What is the current status of trial NCT00883168?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,791 participants. The study started on 2009-04. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00883168?
The interventions under investigation include: Placebo (DRUG), fluticasone propionate (DRUG), azelastineHcl (DRUG), azelastine Hcl/fluticasone propionate (DRUG).
Who is sponsoring clinical trial NCT00883168?
This trial is sponsored by Meda Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.